title: Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties even in the absence of tissue IGF-1.
abstract: Use of recombinant insulin-like growth factor 1 (IGF-1) as a treatment for primary IGF-1 deficiency in children has become increasingly common. When untreated, primary IGF-1 deficiency may lead to a range of metabolic disorders, including lipid abnormalities, insulin resistance, and decreased bone density. To date, results of this therapy are considered encouraging; however, our understanding of the role played by IGF-1 during development remains limited. Studies on long-term treatment with recombinant IGF-1 in both children and animals are few. Here, we used two novel transgenic mouse strains to test the long-term effects of elevated circulating IGF-1 on body size and skeletal development. Overexpression of the rat igf1 transgene in livers of mice with otherwise normal IGF-1 expression (HIT mice) resulted in approximately threefold increases in serum IGF-1 levels throughout growth, as well as greater body mass and enhanced skeletal size, architecture, and mechanical properties. When the igf1 transgene was overexpressed in livers of igf1 null mice (KO-HIT), the comparably elevated serum IGF-1 failed to overcome growth and skeletal deficiencies during neonatal and early postnatal growth. However, between 4 and 16 weeks of age, increased serum IGF-1 fully compensated for the absence of locally produced IGF-1 because body weights and lengths of KO-HIT mice became comparable with controls. Furthermore, micro-computed tomography (microCT) analysis revealed that early deficits in skeletal structure of KO-HIT mice were restored to control levels by adulthood. Our data indicate that in the absence of tissue igf1 gene expression, maintaining long-term elevations in serum IGF-1 is sufficient to establish normal body size, body composition, and both skeletal architecture and mechanical function.
authors.affiliation: Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
authors.forename: Sebastien
authors.initials: S
authors.lastname: Elis
authors.forename: Hayden-William
authors.initials: HW
authors.lastname: Courtland
authors.forename: Yingjie
authors.initials: Y
authors.lastname: Wu
authors.forename: Clifford J
authors.initials: CJ
authors.lastname: Rosen
authors.forename: Hui
authors.initials: H
authors.lastname: Sun
authors.forename: Karl J
authors.initials: KJ
authors.lastname: Jepsen
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Majeska
authors.forename: Shoshana
authors.initials: S
authors.lastname: Yakar
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D019898:Autocrine Communication; D001696:Biomechanical Phenomena; D049628:Body Size; D001842:Bone and Bones / Q000378:metabolism* / Q000473:pathology; D002452:Cell Count; D005786:Gene Expression Regulation; D007334:Insulin-Like Growth Factor I / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008954:Models, Biological; D010006:Osteoblasts / Q000166:cytology / Q000378:metabolism; D010010:Osteoclasts / Q000166:cytology / Q000378:metabolism; D019899:Paracrine Communication; D010521:Periosteum / Q000254:growth & development / Q000378:metabolism; D012741:Sexual Maturation
chemical_list: D007334:Insulin-Like Growth Factor I